nach oben

Targeted Oncology

Erschienen in:

01.03.2012 | Review

Advancement in the research on vascular endothelial growth inhibitor (VEGI)

verfasst von: Lijiao Duan, Ganggang Yang, Ruigang Zhang, Lijuan Feng, Cunshuan Xu

Erschienen in: Targeted Oncology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Vascular endothelial growth inhibitor (VEGI), also known as tumor necrosis factor superfamily member 15 or TNF ligand-related molecule 1, is identified as one kind of antiangiogenic cytokine that belongs to the tumor necrosis factor superfamily. VEGI includes three isoforms: VEGI-174, VEGI-192, and VEGI-251. VEGI can activate multiple signaling pathways including nuclear factor-kappaB, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. Moreover, it suppresses endothelial cell proliferation, angiopoiesis, and tumor growth. Genetic engineering techniques have been used to produce recombinant human vascular endothelial growth inhibitor, and great progress has been made in its application for curing cancer. VEGI could serve as a potential target in the development of angiogenesis-based cancer therapy, and this paper briefly summarizes the progress of the research on VEGI.

Tan KB, Harrop J, Reddy M et al (1997) Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204(1–2):35–46. doi:10.1016/S0378-1119(97)00509-X PubMedCrossRef

Zhai Y, Ni J, Jiang GW et al (1999) VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13:181–189PubMed

Zhai Y, Yu J, Iruela-Arispe L et al (1999) Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82:131–136. doi:10.1002/(SICI)1097-0215 PubMedCrossRef

Chew LJ, Pan H, Yu J et al (2002) A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16:742–744. doi:10.1096/fj.01-0757fje PubMed

Yu J, Tian S, Metheny-Barlow L et al (2001) Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 89:1161–1167. doi:10.1161/hh2401.101909 PubMedCrossRef

Zhang M, Wang L, Wang HW et al (2003) The impact of the deletion of N-terminus of VEGI on its bioactivity. Acta Bioch Bioph Sin 35(2):33–137

Zhang N, Sanders AJ, Ye L et al (2009) Vascular endothelial growth inhibitor in human cancer. Int J Mol Med 24:3–8. doi:10.3892/ijmm-00000198 PubMed

Sethi G, Sung B, Aggarwal BB (2009) Therapeutic potential of VEGI/TL1A in autoimmunity and cancer. Adv Exp Med Biol 647:207–215. doi:10.1007/978-0-387-89520-8_15 PubMedCrossRef

Yang CR, Hsieh SL, Teng CM et al (2004) Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 64:1122–1129. doi:10.1158/0008-5472.CAN-03-0609 PubMedCrossRef

10.

Xiao Q, Hsu CY, Chen H et al (2005) Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388:913–920. doi:10.1042/BJ20041739 PubMedCrossRef

11.

Huang S, Robinson JB, Deguzman A et al (2000) Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60:5334–5339PubMed

12.

Udalova IA, Richardson A, Denys A et al (2000) Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 20:9113–9119PubMedCrossRef

13.

Sammy G, Tian F, Li LY (2009) Sensitization of endothelial cells to VEGI-induced apoptosis by inhibiting the NF-κB pathway. Apoptosis 14:788–795. doi:10.1007/s10495-009-0351-9 CrossRef

14.

Yue TL, Ni J, Romanic AM et al (1999) TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 274:1479–1486. doi:10.1074/jbc.274.3.1479 PubMedCrossRef

15.

Chen CX, Zhuang GH (2006) The progress in researches on VEGI. Chin J Cancer Biother 13(4):308–310 [Article in Chinese]

16.

Parr C, Gan CH, Watkins G et al (2006) Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9:73–81. doi:10.1007/s10456-006-9033-1 PubMedCrossRef

17.

Haridas V, Shrivastava A, Su J et al (1999) VEGI, a new member of the TNF family activates nuclear factor-kappaB and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18:6496–6504PubMedCrossRef

18.

Zhang N, Sanders AJ, Ye L et al (2010) Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res 30:87–95PubMed

19.

Zhang N, Sanders AJ, Ye L et al (2009) Vascular endothelial growth inhibitor, expression in human prostate cancer tissue and the impact on adhesion and migration of prostate cancer cells in vitro. Int J Oncol 35:1473–1480. doi:10.3892/ijo_00000466 PubMedCrossRef

20.

Tian F, Liang PH, Li LY (2009) Inhibition of endothelial progenitor cell differentiation by VEGI. Blood 113:5352–5360. doi:10.1182/blood-2008-08-173773 PubMedCrossRef

21.

Liang PH, Tian F, Lu Y et al (2010) Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors. Angiogenesis 14(1):61–68. doi:10.1007/s10456-010-9195-8 PubMedCrossRef

22.

Lou YH, Jiao BH, Xiao Y et al (2002) Recombinant human soluble VEGI expresses efficiently in E. coli. Acad J Sec Mil Med Univ 23(2):140–142 [Article in Chinese]

23.

Chen X, Wu J, Liu H et al (2010) Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function. Protein Sci 19:449–457. doi:10.1002/pro.323 PubMed

24.

Cai JP, Wei RL, Cheng JW (2008) Preparation and characterization of a novel chimeric protein VEGI-CTT in Escherichia coli. J Biomed Biotechnol 10:1–9. doi:10. 1155/2008/564969 CrossRef

25.

Liu L, Chen YG, Tan LS et al (2001) Secretory expression of human VEGI in Pichia pastoris. Lett Biotechnol 12(2):85–87

26.

Xiao T, Fan JK, Huang HL et al (2010) VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis. Cell Res 20:367–378. doi:10.1038/cr.2009.126 PubMedCrossRef

27.

Li Z, Pan X, Pan W et al (2003) Packaging and identification of recombinant adenovirus vector carrying hENDO-sVEGI. Shijie Huaren Xiaohua Zazhi 11(6):741–744

Titel: Advancement in the research on vascular endothelial growth inhibitor (VEGI)
verfasst von: Lijiao Duan
Ganggang Yang
Ruigang Zhang
Lijuan Feng
Cunshuan Xu
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Targeted Oncology / Ausgabe 1/2012
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-012-0206-0

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Advancement in the research on vascular endothelial growth inhibitor (VEGI)

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

A review on various targeted anticancer therapies

Targeting regulatory T cells

Targeting pattern recognition receptors in cancer immunotherapy

Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival

Recent successes of cancer immunotherapy: a new dimension in personalized medicine?

Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie